TY - JOUR
T1 - Analysis of selective target engagement by small-molecule sphingosine kinase inhibitors using the Cellular Thermal Shift Assay (CETSA)
AU - Hengst, Jeremy A.
AU - Dick, Taryn E.
AU - Smith, Charles D.
AU - Yun, Jong K.
N1 - Funding Information:
This work was supported by the National Institutes of Health (P01 CA171983 to J.K.Y), (P01 CA203628 to C.D.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by the Four Diamonds (to C.D.S.) and The Jake Gittlen Memorial Golf Tournament (to J.K.Y.)
Funding Information:
This work was supported by the National Cancer Institute [CA203628]; National Cancer Institute [CA171983]. This work was supported by the National Institutes of Health (P01 CA171983 to J.K.Y), (P01 CA203628 to C.D.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by the Four Diamonds (to C.D.S.) and The Jake Gittlen Memorial Golf Tournament (to J.K.Y.)
Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - The recently renewed interest in scientific rigor and reproducibility is of critical importance for both scientists developing new targeted small-molecule inhibitors and those employing these molecule in cellular studies, alike. While off-target effects are commonly considered as limitations for any given small-molecule inhibitor, the ability of a given compound to distinguish between enzyme isoforms is often neglected when employing compounds in cellular studies. To call attention to this issue, we have compared the results of an assay for “direct target engagement”, the Cellular Thermal Shift Assay (CETSA), to the published isoform selectivity of 12 commercially available sphingosine kinase 1 and 2 (SphK 1 and SphK2) inhibitors. Our results suggest that, at the concentrations commonly employed in cellular assay systems, none of the tested SKIs can be considered isoform selective. Thus, caution and complimentary assay strategies must be employed to fully discern isoform selectivity for the SphKs. Moreover, caution must be employed by the scientific community as a whole when designing experiments that aim to discern the effects of one enzyme isoform versus another to ensure that the concentration ranges used are able to distinguish isoform selectivity.
AB - The recently renewed interest in scientific rigor and reproducibility is of critical importance for both scientists developing new targeted small-molecule inhibitors and those employing these molecule in cellular studies, alike. While off-target effects are commonly considered as limitations for any given small-molecule inhibitor, the ability of a given compound to distinguish between enzyme isoforms is often neglected when employing compounds in cellular studies. To call attention to this issue, we have compared the results of an assay for “direct target engagement”, the Cellular Thermal Shift Assay (CETSA), to the published isoform selectivity of 12 commercially available sphingosine kinase 1 and 2 (SphK 1 and SphK2) inhibitors. Our results suggest that, at the concentrations commonly employed in cellular assay systems, none of the tested SKIs can be considered isoform selective. Thus, caution and complimentary assay strategies must be employed to fully discern isoform selectivity for the SphKs. Moreover, caution must be employed by the scientific community as a whole when designing experiments that aim to discern the effects of one enzyme isoform versus another to ensure that the concentration ranges used are able to distinguish isoform selectivity.
UR - http://www.scopus.com/inward/record.url?scp=85089686894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089686894&partnerID=8YFLogxK
U2 - 10.1080/15384047.2020.1798696
DO - 10.1080/15384047.2020.1798696
M3 - Article
C2 - 32835586
AN - SCOPUS:85089686894
SN - 1538-4047
VL - 21
SP - 841
EP - 852
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 9
ER -